Sciences
How Does the COVID-19 Antiviral Medications Workflow Compare to the Traditional Antiviral Production Pipeline
As the COVID-19 pandemic continues to progress researchers and scientists are starting to learn more about the virus in order to effectively combat it. One of those lessons is how the COVID-19 virus compares to other viruses when it comes to developing treatments. Justin Honore talked to Dr. Kishor Wasan, PH.D.,FAAPS, FCAHS, FCSPS, Chief…
This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.
Key takeaways
As the COVID-19 pandemic continues to progress researchers and scientists are starting to learn more about the virus in order to effectively combat it.
One of those lessons is how the COVID-19 virus compares to other viruses when it comes to developing treatments.
Kishor Wasan, PH.D.,FAAPS, FCAHS, FCSPS, Chief…
As the COVID-19 pandemic continues to progress researchers and scientists are starting to learn more about the virus in order to effectively combat it. One of those lessons is how the COVID-19 virus compares to other viruses when it comes to developing treatments. Justin Honore talked to Dr. Kishor Wasan, PH.D.,FAAPS, FCAHS, FCSPS, Chief Medical & Scientific Officer at Skymount Medical and a Distinguished University Scholar Adjunct Professor at the University of British Columbia about how COVID-19 vaccine research and production compare to the traditional antiviral and antibiotic production pipeline.
About the author
